Irish Needle Exchange Forum
RSS icon Email icon Home icon
  • International Overdose Awareness 2015

    Posted on August 31st, 2015 TimB No comments

    These two videos are of interviews with individuals who have been affected by Drug Overdose . The interviews are on the theme of Rethink and Remember



  • Request for Expressions of Interest: to carry out an Evaluation of the HSE Naloxone Demonstration Project

    Posted on April 2nd, 2015 TimB No comments

    The HSE has a stated commitment to take actions which focus on reducing the number of drug-related deaths and near-fatal drug poisonings. The HSE is currently finalising a Naloxone Demonstration Project, the purpose of which is to have Naloxone available for use by opioid users in order to prevent overdose. This project meets one of the key actions contained in the Primary Care Division Operational Plan 2015, “Implement a Naloxone Demonstration Project to assess and evaluate its suitability and impact (in line with NDS Action 40).”

    The demonstration project involves 600 patients receiving take-home Naloxone within the current legislative framework.  The product (Prenoxad 1mg/ml injection) is a licensed injectable administered via the parenteral route and formulated in a specific overdose pack. This allows for lay administration. The product is currently available inWales and England.

    A key element of the demonstration project is the provision of training for drug users and those close to them, on the use of Naloxone and on recognising and dealing with overdose events.


  • Best Practice for Overdose Prevention on the release from Prison

    Posted on October 10th, 2014 TimB No comments

    This ‘Fact Sheet’ reports on good practice models in four European Union (EU) countries – Scotland, Denmark, Italy and Spain (more specifically, the Catalonia region) – on overdose prevention and management programmes upon release from prison. The main findings are concluded with recommendations made regarding their relevance to the five target countries of the project: Estonia, Hungary, Lithuania, Poland and Romania.

    Information gathered includes programme descriptions; evidence of effectiveness; functioning; and involvement of people who use drugs. The methodology for collection and documentation of good practices is based on reports and guidance from leading organizations in the field such as the World Health Organization, European Monitoring Centre for Drugs and Drug Addiction
    (EMCDDA) etc. This fact sheet is of particular relevance to prison staff, health care professionals and people who use drugs.


  • Eliza Wheeler talks about the Drug Overdose Prevention and Education (DOPE) Project

    Posted on October 30th, 2013 TimB No comments

    The DOPE Project conducts regular naloxone trainings at syringe exchanges and drop-in programs in San Francisco.

    For more information http://harmreduction.org/our-work/overdose-prevention/bay-area-dope/

  • Opioid overdose: preventing and reducing opioid overdose mortality

    Posted on June 21st, 2013 TimB No comments

    Although data are limited, an estimated 70,000-100,000 people die from opioid overdose each year. Opioid overdose was the main cause of the estimated 99,000- 253,000 deaths worldwide related to illicit drug use in 2010.1 Opioid overdose is
    both preventable and, if witnessed, treatable (reversible). In its resolution 55/7 on promoting measures to prevent drug overdose, in particular opioid overdose, the

    Commission on Narcotic Drugs called upon Member States to include effective measures to prevent and treat drug overdose in national drug policies.2 In that resolution, the Commission requested the United Nations Office on Drugs and Crime (UNODC), in collaboration with the World Health Organization (WHO), to collect and circulate available best practices on the prevention and treatment of and emergency response to drug overdose, in particular opioid overdose, including on the use
    and availability of opioid receptor antagonists such as naloxone and other measures based on scientific evidence.

    This discussion paper outlines the facts about opioid overdose, the actions that can be taken to prevent and treat (reverse) opioid overdose and areas requiring further investigation.


  • The National Drug-related Deaths Database (Scotland) Report 2011

    Posted on May 1st, 2013 TimB No comments

    In 2011, there were 438 cases identified as eligible for inclusion in the NDRDD cohort (an increase from 365 in 2010).

    1. Over three quarters (78.3%) were males, over half (53.4%) had lived in the most deprived areas in Scotland and the 35-44 years age group accounted for the highest proportion of deaths (38.1%)
    2. Over two fifths (44.5%) of the cohort, where known, were a parent or parental figure. A total of 331 children lost a parent or parental figure to a drug-related death.
    3. Where known, nearly two thirds (63%) had a history of intravenous (IV) drug use, which is a lower proportion than in 2010 (70.8%). Over three quarters (77.4%) of the 2011 cohort had a medical condition recorded in the 6 months prior to death. IV drug users had a higher prevalence of medical conditions compared to those who were not known to have been an IV drug user.
    4. The prevalence of Hepatitis C amongst the drug-related deaths cohort has steadily increased over the period 2009-2011.
    5. Where known, almost two thirds of individuals (64.5%) had been in contact with a drug treatment service at some point in their lives.
    6. Where known, in the 6 months prior to death, one third (34.3%) had been released from police custody and almost one fifth (18.1%) had been released from prison.
    7. This year’s report includes data on drugs ‘present’ in the body and drugs ‘implicated’ in the death. The presence of a drug in toxicology of the deceased individual does not necessarily mean that the drug was implicated in (contributed to) the death.
    8. The drug most frequently found to be present in the body at death was diazepam (81.4%) followed by methadone (57.3%), heroin/morphine (51.5%), anti-depressants (37.1%) and alcohol (37.1%). In 97% of cases there was more than one drug present. Opioids (methadone, heroin, morphine or buprenorphine) were present in 87.2% of cases.
    9. The drug most frequently implicated in the death was methadone (53.4%), followed by heroin/morphine (38.6%), diazepam (23.1%) and alcohol (21.2%). More than one drug was implicated in the death in the majority of cases (68.9%).
    10. In relation to drugs present, the proportion of deaths with heroin/morphine and alcohol has decreased over the period 2009-2011, while the proportion of deaths with methadone, diazepam and anti-depressants has increased over this period.
    11. In 2011, the majority of individuals (150, 60.7%) with methadone found in their toxicology were not in receipt of a methadone prescription at the time of death.
    12. Where toxicology information was known, a higher proportion of females (72.3%) had methadone present compared with males (53.1%). This pattern is similar to 2010, (56.6% and 41.8% for females and males respectively), although the gap between females and males has grown in 2011.
    13. Where known, almost three quarters (73.8%) of individuals in the 2011 NDRDD cohort were not currently in receipt of a prescribed substitute drug.

    Download Report

  • Illicit Use of Buprenorphine/Naloxone Among Injecting and Noninjecting Opioid Users

    Posted on October 24th, 2012 TimB No comments

    We examined the use, procurement, and motivations for the use of diverted buprenorphine/naloxone among injecting and noninjecting opioid users in an urban area.

    A survey was self-administered among 51 injecting opioid users and 49 noninjecting opioid users in Providence, RI. Participants were recruited from a fixed-site syringe exchange program and a community outreach site between August and November 2009.

    The use of diverted buprenorphine/naloxone was common in our sample. However, many opioid users, particularly IDUs, were using diverted buprenorphine/naloxone for reasons consistent with its therapeutic purpose, such as alleviating opioid withdrawal symptoms and reducing the use of other opioids. These findings highlight the need to explore the full impact of buprenorphine/naloxone diversion and improve the accessibility of buprenorphine/naloxone through licensed treatment providers.


  • Prehospital Medication Administration: A Randomised Study Comparing Intranasal and Intravenous Routes

    Posted on October 14th, 2012 TimB No comments

    Opioid overdose is an ever-increasing problem globally. Recent studies have demonstrated that intranasal (IN) naloxone is a safe and e?ective alternative to traditional routes of naloxone administration for reversal of opioid overdose.

    This randomised controlled trial aimed to compare the time taken to deliver intranasal medication with that of intravenous (IV) medication by advanced paramedic trainees.


  • The availability of Naloxone in a homeless primary healthcare service in Ireland

    Posted on April 30th, 2012 TimB No comments

    This is an interview with Janet Robinson from Safetynet, in the interview Janet talks about how the service operates and highlights the importance of providing Naloxone in the homeless services.

  • Interview with Sarz Maxwell M.D. of the Chicago Recovery Alliance

    Posted on April 16th, 2012 TimB No comments


    This is a interview with Sarz Maxwell M.D . Sarz Maxwell, M.D., is a psychiatrist with the Chicago Recovery Alliance, and before that, she was with the Center for Addictive Problems methadone clinic in Chicago. The interview covers a variety of issues such as methadone, stigma and discrimination related to those clients on  Methadone Treatment  and Injecting Drug Users, the interview also covers Naloxone the life saving medication and finally chatting about her move to New Zealand .


Google Analytics integration offered by Wordpress Google Analytics Plugin